FL-META0/POLYGON
24.8.2022 16:35:26 CEST | Business Wire | Press release
Meta0 , a new blockchain startup that connects metaverses and blockchain ecosystems through a Layer 0 protocol, has announced an official partnership with Polygon .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220824005476/en/
Polygon is one of the most cost-effective EVM-based blockchains, and also a favorite choice amongst game developers. By partnering with Polygon, Meta0 will provide game devs with all of the advantages of the Polygon platform: low fees, a big user community and a vast decentralized apps (dapp) ecosystem with which to integrate.
The Polygon network has grown over 400% this year, boasting just over 37,000 decentralized dapps — with 74% of teams integrated exclusively on Polygon. The network is fast becoming the de facto platform for Web3 gaming, working with the likes of Ubisoft, Atari, Animoca, Decentraland, Somnium Space, Sandbox, Atari (multiverse), and Aavegotchi among others. Founded by the former global head of TikTok's strategy and gaming unit, Jason Fung, Meta0 provides the tools game developers need to easily reach players on every blockchain while also spending less time, money and personnel on the development process itself. As a one-stop shop for game developers, they remove the technical complexities of blockchain integration by providing intuitive API and SDK-based solutions that offer cross-chain support.
Urvit Goel, Head of Global Games Business Development at Polygon Studios, said: "Meta0 exemplifies the composability required of a truly global metaverse and gaming platform. Polygon's developer toolset and established Blockchain Gaming ecosystem pair well with Meta0's approach, and we're thrilled to be joining together to advance Web3 development, adoption, and interoperability."
"We couldn't be more excited to announce this partnership with Polygon," said Ricardo Rodrigues, Head of Global Partnerships at Meta0. "This is another significant step in expanding Meta0's offering of blockchain interoperability and access to more gamers for game devs everywhere who want to make the best Web3 gaming experiences."
About Meta0:
Meta0 is a blockchain infrastructure company that advances interoperability by connecting different chains and metaverses through a Layer 0 protocol. The company makes blockchain integrations easy for game developers through white-label, API, and SDK-based solutions, so that they can focus on building fun-to-play Web3 games and on creating experiences that gamers enjoy. Learn more about Meta0 at www.meta0.org .
Twitter | Discord | Telegram | LinkedIn
About Polygon Studios:
Polygon Studios aims to be the home of the most popular blockchain projects in the world. The Polygon Studios team is focused on supporting developers building decentralized apps on Polygon by providing Web2 and Web3 teams with a suite of services such as developer support, partnership, strategy, go-to-market, and technical integrations. Polygon Studios supports projects from OpenSea to Prada, from Adidas to Draft Kings and Decentral Games to Ubisoft.
Twitter | Facebook | Instagram | Telegram | TikTok | LinkedIn
About Polygon:
Polygon is the leading blockchain development platform, offering scalable, affordable, secure and sustainable blockchains for Web3. Its growing suite of products offers developers easy access to major scaling solutions including L2 (ZK Rollups and Optimistic Rollups), sidechains, hybrid, stand-alone and enterprise chains, and data availability. Polygon’s scaling solutions have seen widespread adoption with 37,000+ decentralized applications hosted, 1.94B+ total transactions processed, 164M+ unique user addresses, and $5B+ in assets secured. The network is home for some of the biggest Web3 projects such as Aave, Uniswap, OpenSea and well-known enterprises including Meta, Stripe and Adobe. Polygon is carbon neutral with the goal of leading the Web3 ecosystem in becoming carbon negative.
If you're an Ethereum Developer, you're already a Polygon developer! Leverage Polygon’s fast and secure txns for your dapp, get started here .
Website | Twitter | Ecosystem Twitter | Developer Twitter | Studios Twitter | Telegram | LinkedIn | Reddit | Discord | Instagram | Facebook
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005476/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom